Exploratory Analysis of ctDNA in MIBC from CheckMate 274
Panelists explore the latest insights on CTDNA in muscle-invasive bladder cancer and its impact on immunotherapy decision-making and patient outcomes.
Dr. Joshua Meeks and Dr. Alan Tan begin this program by exploring circulating tumor DNA (ctDNA) in muscle-invasive bladder cancer. They contextualize the disease's complexity, emphasizing its high recurrence rates and systemic nature. Current treatment approaches face significant limitations in identifying patients who truly need intensive therapy versus those potentially curable by surgery. The discussion reveals how molecular testing might revolutionize patient management by providing more precise risk stratification. Dr. Tan highlights the challenges of traditional staging, suggesting a paradigm shift toward molecularly-guided treatment strategies. The experts examine how ctDNA could potentially differentiate between patients requiring aggressive intervention and those who might benefit from more conservative approaches. Their dialogue underscores the emerging potential of precision medicine in understanding muscle-invasive bladder cancer's intricate biological landscape.
